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ABSTRACT
Uncontrolled cell growth in Tuberous Sclerosis Complex occurs due to 
inappropriate activation of mechanistic (mammalian) target of rapamycin complex 
1 (mTORC1). The current therapy, rapamycin, produced promising clinical trial 
results, but patient tumours regrow if treatment is discontinued, revealing rapamycin 
has cytostatic properties rather than a cytotoxic effect. Taking advantage of the 
enhanced levels of endoplasmic reticulum (ER) stress present in TSC2-null cells, we 
investigated drug combinations producing a cytotoxic response. We found a nelfinavir 
and salinomycin combination specifically killed TSC2-deficient, mTORC1 hyperactive 
cells. Cytotoxicity was rescued by reducing protein synthesis, either through mTORC1 
inhibition or cycloheximide treatment. This indicates that the drug combination targets 
the cells by tipping the protein homeostasis balance of the already metabolically 
stressed TSC2-deficient cells in favour of cell death. Furthermore, this drug 
combination also inhibited tumour formation in TSC2-deficient cell models and caused 
tumour spheroid death in 3D culture. Importantly, the 3D assay could differentiate the 
cytostatic agent, rapamycin, from the cytotoxic nelfinavir/salinomycin combination. 
Sporadic cancer cell lines with hyperactive mTORC1 signalling were also susceptible 
to this nelfinavir/salinomycin drug combination. This work indicates that the protein 
homeostasis pathway is an attractive therapeutic target in both Tuberous Sclerosis 
Complex and mTORC1-driven sporadic cancers.
INTRODUCTION
The mechanistic (mammalian) target of rapamycin 
complex 1 (mTORC1) is a central regulator of cell growth, 
via its control of protein synthesis and other anabolic 
pathways. The tumour suppressors, Tuberous Sclerosis 
Complex (TSC)-1 and TSC2, lie upstream of mTORC1 
and function together with TBC1D7 to negatively regulate 
the mTORC1 activator, Ras homolog enriched in brain 
(Rheb). Mutations in TSC1 or TSC2 lead to the rare 
genetic condition, TSC, where patients develop cysts and 
tumours in multiple organs due to mTORC1 hyperactivity 
and uncontrolled cell growth. mTORC1 signalling is also 
inappropriately activated in a number of sporadic cancers 
(reviewed in 1). For example, over half of breast cancers 
demonstrate upregulated markers of mTORC1 activation, 
such as phospho-S6K1 and phospho-ribosomal protein S6 
(rpS6) [2, 3], while overexpression of mTORC1 substrates 
are also strongly associated with prostate cancer [4]. 
mTORC1 upregulation in such cancers could be due to 
mutations in a number of upstream oncogenes and tumour 
suppressors, including those controlling the PI3K-Akt 
or MAPK signalling pathways which both converge on 
mTORC1. mTORC1 activation specifically through 
TSC loss of function is seen in a proportion of bladder 
cancer [5], hepatocellular carcinoma [6] and pancreatic 
neuroendocrine tumours [7].
Rapamycin is an allosteric small molecule 
inhibitor of mTORC1 and is an effective treatment for 
TSC angiomyolipomas [8, 9]. However, it has been 
shown that discontinuation of patient treatment leads to 
tumour regrowth, indicating that rapamycin functions 
as a cytostatic agent. Instead of inhibiting mTORC1, 
an alternative strategy for TSC therapy is to exploit the 
metabolic vulnerabilities of mTORC1 hyperactive cells, 
which would instigate a cytotoxic response. For example, 
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TSC-deficient cells are highly sensitive to glucose 
withdrawal and undergo glucose deprivation-induced death 
[10]. Additionally, inhibition of glutaminase sensitises 
TSC2-deficient cells to heat shock protein 90 (HSP90) 
inhibition through a mechanism of increased oxidative 
stress [11]. A potential therapeutic avenue is to exploit the 
fact that mTORC1 hyperactive cells have enhanced basal 
endoplasmic reticulum (ER) stress, due to the elevated 
levels of mTORC1-directed protein synthesis placing 
a burden on the protein folding capacity of the ER. ER 
stress activates a protective pathway termed the unfolded 
protein response (UPR), which aims to downregulate 
protein synthesis and restore protein folding in order 
to restore cellular homeostasis. However, following 
excessive ER stress over a prolonged period, apoptosis 
is initiated [12]. A key player in the ER stress response 
is C/EBP homologous protein (CHOP, also called growth 
arrest and DNA damage inducible gene 153 (GADD153)) 
[13]. Upon acute ER stress, CHOP expression is strongly 
enhanced through IRE1α- and PERK-mediated pathways. 
If homeostasis is not restored and the levels of misfolded 
proteins remain high, CHOP stimulates a transcriptional 
programme that instigates cell death [12]. Amongst other 
genes, CHOP directly activates expression of GADD34 
[14], a protein phosphatase 1 (PP1) regulator which 
causes PP1-mediated dephosphorylation of eIF2α [15]. 
This releases the translational block, thereby enhancing 
protein synthesis to activate death-associated mechanisms. 
Further enhancing ER stress through treatment with ER 
stress inducing drugs has been shown to selectively induce 
the death of mTORC1 hyperactive cells [16]. 
Recently, salinomycin has been identified as a potent 
mediator of breast cancer stem cell death [17]. Follow up 
studies by other groups indicate that it also induces cell 
death in bulk cancer cell lines [18-22]. Salinomycin is 
a potassium ionophore, but the mechanism by which it 
induces cell death is not yet clear, with unconventional 
cell death pathways implicated in its mode of action [18]. 
Several cell signalling pathways are reported to be altered 
following salinomycin treatment, including enhancement 
of ER stress [21], inhibition of Wnt signalling [22] and an 
impact on autophagy [23]. Salinomycin has been reported 
to inhibit mTORC1 signalling in breast, prostate and 
lung cancer cell lines [19, 21]. Interestingly, when CDH1 
expression is inhibited in non-small cell lung carcinoma 
cells, salinomycin induces more cell death than in their 
wildtype counterparts as mTOR inhibition is alleviated 
in these cells [21]. This work implies that cells with a 
higher level of mTORC1 activity are more sensitive to the 
cytotoxic drug action of salinomycin.
The current study tests the impact of salinomycin 
treatment on mTORC1 hyperactive cells. We did this in 
combination with nelfinavir, as TSC2-deficient cells have 
previously been reported to be selectively targeted by 
nelfinavir treatment [16, 24]. Nelfinavir inhibits the human 
immunodeficiency virus (HIV) retroviral protease and is 
widely used to treat HIV infection. Studies have revealed 
that nelfinavir can exert multiple cellular effects, such 
as induction of autophagy and apoptosis in cancer cell 
lines [25]. Herein, we examined the synergistic potential 
of nelfinavir and salinomycin to selectively kill TSC2-
deficient cells and tested the dependence of mTORC1 
hyperactivation as a sensitising mechanism of drug 
cytotoxicity. We also employed 3D cell spheroid models to 
measure tumour shrinkage post-drug treatment and further 
examined the concept of cytotoxic versus cytostatic drug 
action, using DRAQ7 as the unified signal readout of cell 
viability across all the models from 2D to 3D. Our work 
highlights the therapeutic potential of ER stress inducers 
that show selective cytotoxicity in mTORC1 hyperactive 
cells.
RESULTS
Combined nelfinavir and salinomycin treatment 
induces ER stress
As both nelfinavir and salinomycin as single 
agents have been reported to induce ER stress in other 
cell lines [21, 25], we determined their impact alone 
and in combination in both Tsc2-/- and Tsc2+/+ MEFs. To 
examine the relative levels of ER stress burden, a series of 
downstream ER stress markers were assessed after 6 h of 
drug treatment. mRNA levels of CCAAT-enhancer-binding 
protein homologous protein (CHOP), HSP70, and ER 
degradation enhancer mannosidase alpha-like 1 (EDEM1) 
were measured (Figure 1A-1C). Significantly higher basal 
gene expression of these ER stress markers was observed 
in the Tsc2-/- MEFs when compared to wild-type cells, as 
previously reported [16, 31]. While nelfinavir enhanced 
mRNA expression in both cells, mRNA expression was 
elevated to a much higher level in the Tsc2-/- MEFs. As a 
single agent, salinomycin induced an increase in CHOP 
expression in both cell lines, but had little impact on 
HSP70 or EDEM1 mRNA levels. Protein levels of IRE1α 
and ATF4 were also elevated upon single or combined 
treatment with nelfinavir and salinomycin (Figure 1D). 
To further assess ER stress, we examined XBP1 splicing 
(Figure 1E-1F). As part of the UPR during ER stress, 
IRE1α catalyses the excision of an unconventional intron 
within XBP1 mRNA that can be measured via PCR. In 
the Tsc2-/- MEFs, the lower spliced XBP1 PCR product 
(loss of 26 nucleotides) is the predominant XBP1 mRNA 
form after nelfinavir treatment, while only 40 % (± 4 %) 
of XBP1 mRNA was spliced in the wild-type controls. 
Combined nelfinavir/salinomycin treatment caused a 
further 16 % increase in XBP1 splicing in wild-type cells, 
though could not further enhance the already high level of 
XBP1 splicing seen in the nelfinavir treated Tsc2-/- MEFs. 
This data demonstrates that nelvinavir and/or salinomycin 
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can induce a high level of ER stress in cells lacking Tsc2.
Salinomycin synergises with nelfinavir to 
selectively kill Tsc2-/- MEFs
Extended periods of ER stress can lead to cellular 
death if not efficiently restored [12]. To quantify cell death 
after drug treatments, we carried out flow cytometry with 
DRAQ7 (Figure 2A, graphed in Figure 2B). DRAQ7 is 
a membrane impermeable far-red fluorescent dye which, 
when membrane integrity is compromised, enters the cell 
and binds readily to nuclear DNA to report cell death [32, 
33]. As a single agent, salinomycin induces a moderate 
percentage of cell death in the Tsc2-/- MEFs (25 % ± 2 
%), while no apparent cytotoxicity was observed in the 
wild-type controls. When nelfinavir was combined with 
salinomycin, we observed a dramatic induction of cell 
death in the Tsc2-/- MEFs. Of interest, combined treatment 
with nelfinavir and salinomycin did not induce cell 
death in the Tsc2+/+ MEFs, which was equivalent to the 
DMSO treated controls (at about 5% in both cases). To 
further confirm that combined nelfinavir and salinomycin 
treatment induced cytotoxicity as a consequence of Tsc2 
loss, we utilised ELT3 cells. ELT3 cells are derived from 
an Eker rat uterine leiomyoma that are Tsc2-null (referred 
to as ‘ELT3-V3’). We compared these Tsc2-null cells to 
a TSC2 re-expressing rescued control cell line (referred 
to as ‘ELT3-T3’ [27]). As observed in the MEFs, ELT3 
cells lacking Tsc2 displayed a higher level of cell death, 
while the TSC2 re-expressing ELT3 cells better tolerated 
nelfinavir and salinomycin as either single treatments or 
when combined (Figure 2C-2D). 
Having demonstrated that combined nelfinavir and 
salinomycin treatment is effective at killing cells lacking 
Tsc2, we next wanted to determine the property of drug 
synergy between nelfinavir and salinomycin. To do this, 
we treated both Tsc2-/- and Tsc2+/+ MEFs with a broad range 
of drug concentrations of nelfinavir and salinomycin as 
single agents and in combination. Cell death was similarly 
assessed using flow cytometry and DRAQ7 labelling. 
The Tsc2-/- MEFs were observed to be acutely sensitive 
to combined treatment with nelfinavir and salinomycin 
and at much lower drug concentrations (Figure 2F), 
while the Tsc2+/+ MEFs tolerated even the highest of drug 
Figure 1: ER stress is elevated by nelfinavir and salinomycin treatment. Tsc2+/+ and Tsc2-/- MEFs were treated with either 
DMSO vehicle, 20 μM nelfinavir (NFV) or 5 μM salinomycin (Sal) as single agents or in combination for 6 h. Gene expression of CHOP 
A., HSP70 B. and EDEM1 C. was determined by real time PCR and relative mRNA expression was standardised to β-actin. Cells which 
had undergone treatment for 24 h were tested for the protein expression of IRE1α and AFT4, with β-actin and total TSC2 as controls D.. 
PCR products of spliced and unspliced XBP1 following 6 h drug treatment were resolved on agarose gels (unspliced = 480 bp upper band, 
spliced = 454 bp lower band) E. and quantified in F.. * p<0.05, **p<0.01, ***p<0.001.
Oncotarget4www.impactjournals.com/oncotarget
concentrations (Figure 2E). CompuSyn software was used 
to calculate combination index (CI) values based on mean 
cell death and is presented as a Chou-Talalay plot (Figure 
2G). CI values below 1 indicate synergistic drug action 
between nelfinavir and salinomycin. Importantly, we 
found that nelfinavir and salinomycin acted in a synergistic 
manner to kill Tsc2-/- MEFs, but no synergy was observed 
in the Tsc2+/+ MEFs.
Figure 2: Dual nelfinavir/salinomycin treatment kills TSC2-/- MEFs synergistically. Tsc2+/+ and Tsc2-/- MEFs were treated with 
either DMSO vehicle, 20 μM nelfinavir (NFV) or 5 μM salinomycin (Sal) as single agents or in combination for 24 h and cell death was 
assessed by flow cytometry using DRAQ7 A., quantified in B. ELT3-V3 and TSC2-re-expressing ELT3-T3 cells were similarly treated for 
48 h and analysed for cell death C., D. Synergy was assessed by examining cell death across a range of salinomycin concentrations, with 
or without 20 µM nelfinavir E., F. and calculated using CompuSyn software G.. Graphs show an average of three independent replicates, 
mean +/- S.E.M. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Nelfinavir and salinomycin dual treatment kills 
cells in an mTORC1-dependent manner
To determine whether mTORC1 activation 
following Tsc2 loss was responsible for the selective 
sensitivity of the cells to nelfinavir/salinomycin dual 
treatment (rather than via another TSC2 function), we 
used rapamycin (an allosteric mTORC1 inhibitor) to 
block mTORC1 signalling. Treatment with rapamycin 
substantially rescued cell death in the Tsc2-/- MEFs 
(Figure 3A and graphed in Figure 3B). Inhibiting mTOR 
also partially rescued nelfinavir and salinomycin induced 
cell death in the ELT3-V3 cells (Figure 3C and graphed in 
Figure 3D). This data indicates that hyperactive mTORC1 
contributes to nelfinavir and salinomycin-induced 
cytotoxicity.
Nelfinavir and salinomycin induce cell death 
through an increased protein synthesis burden
Studies in multiple cell lines have implicated 
different mechanisms of salinomycin induced cell death 
[18-22]. To elucidate which processes may be involved 
in Tsc2-deficient cells, we firstly examined mTORC1 and 
AMPK signalling. We found that as single agents, the 
weak mTORC1 signalling in Tsc2 wild-type cells could be 
inhibited, but neither drug alone impacted substantially on 
S6K1, rpS6 or 4E-BP1 phosphorylation in Tsc2-deficient 
cells. The combination could reduce both phospho-4E-
BP1 and phospho-S6K1 levels in Tsc2-deficient cells after 
24 h, together with the downstream substrate, phospho-
rpS6 (Figure 4A and also seen in Figure 3B). Interestingly, 
the dual treatment also impacted the total levels of S6K1, 
but only in the Tsc2-deficient cells. AMPK activity, as 
measured via phospho-ACC, was elevated following 
single or combination treatments (Figure 4A), indicating 
enhanced energy stress following treatment. Nelfinavir 
has previously been shown to impair the proteasome [34], 
whereas salinomycin’s action appears to be independent of 
the proteasome [18]. To assess how the drug combination 
impacted the proteasome in our cells, we measured the 
proteasomal chymotrypsin-like activity (Figure 4B). 
We generally observed a higher level of proteasome 
activity in the Tsc2-/- MEFs, but there were no significant 
changes to activity upon drug treatment, indicating that 
nelfinavir/salinomycin-induced cell death is independent 
of the proteasome. To determine if cell death involved 
the classical caspase cascade, we analysed cleavage of 
PARP and caspase 3. Salinomycin caused mild PARP and 
caspase-3 cleavage in the Tsc2-/- MEFs as a single agent 
that was not further enhanced upon nelfinavir treatment 
Figure 3: Dual treatment kills cells in a mTORC1-dependent manner. Tsc2+/+ and Tsc2-/- MEFs were treated with DMSO or a 20 
μM nelfinavir (NFV) plus 5 μM salinomycin (Sal) combination for 24 h, with or without the mTOR inhibitor, rapamycin (Rap). Cell death 
was assessed by flow cytometry and mTORC1 inhibition was determined by western blotting for phospho-S6K1 (T389) and phospho-4E-
BP1 (Ser65) A. and B. Similar analysis of ELT3 cells was performed following 48 h drug treatment, with phospho-S6K1 used as a readout 
of mTORC1 activity C. and D. Graphs show an average of three independent replicates, mean +/- S.E.M. **p<0.01, ***p<0.001.
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(Supplemental Figure 1). This suggests an alternative, 
non-classical cell death mechanism is largely responsible 
for nelfinavir/salinomycin-induced cytotoxicity.
Levels of GADD34, which is upregulated in 
response to ER stress, have been shown to correlate with 
cell death [35] and GADD34 overexpression reduces cell 
viability when combined with irradiation [36]. Therefore, 
we assessed GADD34 levels in Tsc2 MEFs following drug 
treatment. We found that nelfinavir strongly enhanced 
GADD34 expression, in keeping with an induction of ER 
stress (Figure 4C). While salinomycin modestly enhanced 
GADD34 levels as a single agent, combination treatment 
Figure 4: Mechanisms of nelfinavir/salinomycin-induced cell death. Following a 24 h incubation with the indicated treatments, 
Tsc2+/+ and Tsc2-/- MEFs were lysed and protein levels of phosphorylated S6K1, rpS6, 4E-BP1 and ACC were determined by western 
blot. Total TSC2, S6K1, rpS6, 4E-BP1, ACC and β-actin are shown as controls A.. The proteasome activity of drug treated samples was 
determined by monitoring the turnover of the fluorescent chymotrypsin-like substrate B.. Samples prepared as in A were further analysed 
for total GADD34, phospho-FOXO3a, phospho-PRAS40 and phospho-Bad. Tsc2+/+ and Tsc2-/- samples were run on the same gel and are 
shown at the same exposure C.. Tsc2+/+ and Tsc2-/- MEFs were pre-treated with cycloheximide (CHX) for 1 h, then treated with the indicated 
combinations for 24 h. Cell death was assessed by flow cytometry D.. *** p < 0.001.
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showed a higher level of GADD34 expression than with 
salinomycin alone. While increased GADD34 did not 
completely correlate with cell death in Tsc2 MEFs, we 
were interested to observe that rapamycin pre-treatment 
of the cells prevented the upregulation of GADD34 
seen in dual nelfinavir/salinomycin treated cells. This 
Figure 5: Dual nelfinavir/salinomycin treatment is effective in 3D models. Tsc2-/- MEFs A. or TSC-null AML cells B. were 
grown in soft agar and treated with DMSO, 10 µM nelfinavir (NFV), 2 µM salinomycin (Sal) or a NFV/Sal combination for 11 days. Images 
of the colonies were taken and the diameters measured using Image J. The scale bar represents 50 µm. Tsc2-/- MEFs were allowed to self-
aggregate into spheroids under non-adherent conditions and were treated with DMSO, 10 µM nelfinavir (NFV) plus 2 µM salinomycin 
(Sal) in combination or 25 nM rapamycin (Rap), as indicated, for 96 h. DRAQ7 was added for the final 36 h to monitor cell death. DRAQ7 
images were taken and quantified C.. Spheroid diameter was determined from phase contrast images taken after 96 h drug treatment and 
plotted against DRAQ7 staining intensity D.. Spheroids were then replated onto standard tissue culture plates and allowed to grow under 
drug free conditions. Images were taken every 24 h and the area of outgrowth calculated using Image J E.. The scale bar represents 200 µm. 
Spheroid experiments were repeated in ELT3-V3 cells (F-H). ***p<0.001, NS = not significant.
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could indicate that the reduction in cell death following 
rapamycin treatment (Figure 3) is due to a reduced burden 
of ER stress in these cells. In neurons, it was found that 
GADD34 could reduce Akt phosphorylation [37]. As Akt 
activation and the downstream phosphorylation of proteins 
such as Foxo3a and BAD is viewed as pro-survival, we 
assessed FOXO3a phosphorylation at the S256 Akt site. 
We found that phospho-FOXO3a levels showed the 
inverse pattern to GADD34 levels, being reduced in Tsc2-
/- MEFs following combination nelfinavir/salinomycin 
treatment and enhanced when cells were pre-treated to 
inhibit mTORC1 prior to nelfinavir/salinomycin treatment 
(Figure 4C). Similarly, the Akt-induced phospho-PRAS40 
site (Thr246) and phospho-BAD site (Ser136) were 
increased with rapamycin pre-treatment compared to 
nelfinavir/salinomycin treatment alone. This suggests that 
high ER stress induced through nelfinavir/salinomycin 
treatment of mTORC1 hyperactive cells correlates with 
a decrease in pro-survival Akt signalling, which could be 
one of the mechanisms by which the treatments induce 
cell death.
The ER stress responsive proteins, ATF4 and CHOP, 
have been shown to cause increased protein synthesis, 
leading to a reduction in cell survival [38]. As we observed 
nelfinavir and salinomycin enhanced CHOP mRNA 
expression (Figure 1A) and ATF4 protein levels (Figure 
1D), we investigated whether the enhanced burden of 
protein synthesis present in Tsc2-deficient cells combined 
with the treatment-induced elevation of CHOP and ATF4 
could play a role in causing cell death. Pharmacological 
inhibition of protein synthesis using cycloheximide 
substantially rescued ( > 60 %) nelfinavir/salinomycin 
induced Tsc2-deficient cell death (Figure 4D), which was 
comparable to rapamycin (Figure 3).
Nelfinavir and salinomycin show cytotoxity 
towards Tsc2-null tumour spheroid models while 
rapamycin acts as a cytostatic agent
To determine whether the drug combination was 
successful in a 3D setting, we next tested nelfinavir 
and salinomycin within Tsc2-deficient tumour spheroid 
model systems. We observed that salinomycin as a single 
agent could markedly block tumour spheroid formation 
of Tsc2-/- MEFs in soft agar (Figure 5A) as well as TSC-
patient derived AML cells that also lack Tsc2 (Figure 5B). 
Combined treatment of salinomycin with nelfinavir was 
equally as potent at reducing tumour formation. Due to 
the longer time period of the experiment compared to the 
monolayer cultures, we found that lower concentrations 
of both drugs were effective at causing cell death in 
our 3D systems. We next wanted to assess whether 
established spheroids were also sensitive to nelfinavir and 
salinomycin. To do this, Tsc2-/- MEF tumour spheroids 
were allowed to form over 72 h and then treated for 4 
days with either DMSO, nelfinavir/salinomycin, or 
rapamycin. Spheroids were stained with DRAQ7 to 
measure the relative levels of cell death (Figure 5C). We 
observed distinct tumour spheroid populations after both 
nelfinavir/salinomycin or rapamycin treatments, with 
marked differences in DRAQ7 staining intensity as well 
as relative spheroid area (Figure 5D). While rapamycin 
caused a marked reduction in spheroid size, there was 
little apparent cell death, as observed by a slight increase 
in DRAQ7 staining that was not significantly different 
to untreated cells (DMSO). In contrast to rapamycin, 
dual nelfinavir and salinomycin treatment caused a 
slight increase in spheroid size due to the development 
of a more uneven spheroid surface. Furthermore, there 
was a significant level of cell death after nelfinavir and 
salinomycin treatment, as observed by a high level of 
DRAQ7 staining within the tumour core (Figure 5C). 
After cessation of drug treatment and re-plating into 
adherent plates, we measured outgrowth of cells from 
these spheroids (Figure 5E). This provided another readout 
of tumour recovery and long-term pharmacodynamics 
consequence of the original drug treatment. Of note, 
we observed cell outgrowth from spheroids that were 
previously treated with rapamycin, revealing a significant 
degree of cell recovery. This property, combined with low 
levels of cell death, indicates that rapamycin is acting as a 
cytostatic agent. As no cell outgrowth was observed over 
the 72 h period from the spheroids previously treated with 
nelfinavir and salinomycin, this drug combination has 
cytotoxic properties throughout the entire spheroid. This 
experiment was repeated using ELT3-V3 cells (Figure 5F-
5H), revealing an identical pattern and supporting the view 
that nelfinavir/salinomycin is a cytotoxic combination to 
TSC2-deficient spheroids.
Sporadic cancers with hyperactive mTORC1 
are also killed by dual nelfinavir/salinomycin 
treatment
As our data indicates that blockade of mTORC1 
signalling allows cells to evade nelfinavir/salinomycin-
induced death, it follows that other cell types with high 
levels of mTORC1 activity should also be sensitive to the 
drug combination. To test this concept further, we utilised 
two cell lines with basally high mTORC1 signalling 
(Figure 6): the NCI-H460 large cell lung cancer cell 
line which has PI3KCA, CDKN2A, STK11 and KRAS 
mutations [39] and the HCT116 colorectal cancer cell 
line, which contains an activating RAS mutation [40] and 
PIK3CA mutation [41]. In both cell lines, dual nelfinavir/
salinomycin treatment significantly enhanced cell death. 
The addition of rapamycin to combined treatment rescued 
33-57 % of cell death (Figure 6A-6B). We also observed 
a strong induction of GADD34 expression in both cell 
lines with dual nelfinavir/salinomycin treatment, which 
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was substantially reduced with rapamycin treatment. This 
implies that an increased ER stress burden may contribute 
to cell death in these mTORC1 hyperactive sporadic 
cancers.
DISCUSSION
Our work shows that targeting the ER stress 
vulnerability of mTORC1 hyperactive cells has promise 
for the eradication of such cells in Tuberous Sclerosis 
Complex and cancer. We found that nelfinavir and 
salinomycin act synergistically to selectively kill Tsc2-
null MEFs, while normal cells with intact Tsc2 tolerate 
treatment (Figure 2). Cytotoxicity is not through the 
classical apoptotic caspase cascade as minimal PARP 
and caspase 3 cleavage were observed following dual 
drug treatment. This fits with a previous report where 
a non-classical mechanism of cell death was observed 
following salinomycin treatment in other cell types [18]. 
Additionally, as Tsc2 MEFs are TP53-null, our data 
indicates that nelfinavir/salinomycin induced cell death is 
independent of p53, fitting with a previous study where 
salinomycin showed cytotoxic properties in TP53-null 
Jurkat cells [18]. Salinomycin’s mode of action is also 
not through proteasomal inhibition, as it did not impact 
proteasomal turnover (Figure 4B), supporting the findings 
of others [18]. 
Figure 6: Sporadic cancer cell lines with hyperactive mTORC1 are also sensitive to nelfinavir and salinomycin. 
Cell death of NCI-H460 cells was determined by flow cytometry following 48 h incubation with 20 μM nelfinavir (NFV) and/or 5 μM 
salinomycin (Sal), with or without 1 h rapamycin (Rap) pre-treatment A.. Cell lysates collected after 24 h treatment were analysed for 
mTORC1 activation (phosphorylated S6K1 and 4E-BP1) and total GADD34 levels A.. Experiments were repeated in HCT116 cells B.. 
*** p < 0.001.
Oncotarget10www.impactjournals.com/oncotarget
Regulation of protein synthesis and cell death have 
been linked previously [38, 42], with ATF4 and CHOP 
reported to have important roles. A block in protein 
synthesis through knockdown of ribosomal genes or 
pharmacological inhibition has been shown to increase 
cell viability in ATF4/CHOP over-expressing cells [38]. 
When we inhibited protein synthesis by downregulating 
mTORC1 signalling with rapamycin (Figure 3) or by 
using cycloheximide (Figure 4D), we were able to 
significantly rescue nelfinavir/salinomycin induced cell 
death. Other studies have shown that increased protein 
synthesis leads to ATP depletion [38] and in accordance 
with this, we observe an elevation of AMPK signalling 
following nelfinavir/salinomycin dual treatment (Figure 
4A). We also observed an increase in phosphorylation of 
the pro-survival Akt substrates FOXO3a, PRAS40 and 
BAD [43], together with a reduction in ER stress burden, 
as measured by GADD34 expression, when mTORC1 
was inhibited in TSC2-null MEFs prior to dual nelfinavir/
salinomycin treatment (Figure 4C). This suggests that high 
protein synthesis resulting in low cellular energy levels 
and decreased survival signalling could be one pathway 
responsible for sensitising TSC2-null cells to nelfinavir/
salinomycin induced death. 
There is much interest in the potential use of 
salinomycin in humans following its identification as an 
agent which could target cancer stem cells [17]. Although 
a review article highlighted two promising case reports 
of its use in cancer patients who had exhausted other 
therapeutic options [44], salinomycin is unlikely to rapidly 
translate to clinical use as there is a lack of mammalian 
safety data and previous reports indicate severe toxicity 
following accidental human exposure [45]. While some 
new salinomycin esters and diastereoisomers have been 
synthesised which also exhibit anti-cancer properties [46, 
47], they still show evidence of neurotoxicity in mice. 
Currently, the specific protein target of salinomycin is 
unknown. Should it be uncovered, it may be possible to 
target the signalling pathway with an alternative drug, 
which in combination with nelfinavir, could prove to be 
a clinically viable combination with specificity for killing 
mTORC1 hyperactive cells.
In this study, 3D colony formation and spheroid 
assays permitted us to determine whether the nelfinavir/
salinomycin induced cell death we observed in monolayer 
cell culture could be replicated in a more physiological 
3D model, an important step in pre-clinical drug testing. 
We found salinomycin either alone, or in combination 
with nelfinavir, effectively blocked colony formation in 
soft agar (Figure 5A-5B). Rapalogues, the current therapy 
for TSC, result in a cytostatic rather than a cytotoxic 
clinical response. Our 3D spheroid system depicts this 
shortcoming of using rapamycin to treat TSC patient 
tumours, as growth recovery was apparent upon its 
removal, showing that rapamycin is a cytostatic agent 
(Figure 5). In contrast to rapamycin, dual nelfinavir/
salinomycin treatment caused complete tumour death 
(Figure 5). This data clearly shows that the nelfinavir 
and salinomycin drug combination is highly cytotoxic to 
mTORC1 hyperactive cells. 
This work also highlights the essential steps of using 
3D culture models in dissecting the pharmacodynamic 
consequences on TSC tumours. The nelfinavir/
salinomycin combination did not shrink the spheroid 
size, unlike rapamycin, and so in other tumour models 
may have been discarded as an ineffective therapy. 
However, by embedding the non-toxic viability label, 
DRAQ7, directly into the treatment timecourse, combined 
with the additional validation of the outgrowth assay, 
it was clear that the cells forming these spheroids were 
no longer viable. In contrast, the rapamycin treated 
spheroids immediately began to regrow following drug 
removal. This spheroid assay shows the importance of 
discriminating between cytostatic treatments and those 
which are likely to bring about a long-lasting cytotoxic 
response, making it an innovative and useful screening 
tool for future TSC therapies. 
MATERIALS AND METHODS
Tissue culture and drug treatments
Tsc2+/+ p53-/- and Tsc2-/- p53-/- mouse embryonic 
fibroblasts (MEFs) were a kind gift from David 
Kwiatkowski (Harvard University, Boston, USA) in 
2004 and have been previously characterised [26]. Eker 
rat leiomyoma-derived Tsc2-deficient ELT3-V3 cells 
and matching control TSC2-expressing ELT3-T3 cells 
generated in Astrinidis et al, 2002 [27], were kindly 
provided in 2006 by Cheryl Walker (M.D. Anderson 
Cancer Center, Houston, USA). Human lung carcinoma 
(NCI-H460) cells were purchased from ATCC in 2012 
while HCT116 cells were provided in 2015 by Nick Leslie 
(Heriot Watt University, Edinburgh). All cell lines were 
mycoplasma free and regularly tested for mycoplasma 
infection using the Venor GeM Classic PCR kit from 
CamBio. Cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM), supplemented with 10 % 
(v/v) foetal bovine serum (FBS), 100 U/ml penicillin and 
100 µ/ml streptomycin (Life Technologies Ltd., Paisley, 
UK) in a humidified incubator at 37 °C, 5 % (v/v) CO2. 
Angiomyolipoma (AML) cells 621-102 were a kind gift 
from Elizabeth Henske (Brigham and Women’s Hospital, 
Boston, U.S.A.) in 2013 and were cultured as above, but 
in media containing 15% FBS. Cell lines were cultured 
for no more than 3 months following their initial thawing. 
Nelfinavir mesylate hydrate, salinomycin (ready-made 
solution) and rapamycin were purchased from Sigma-
Aldrich Company Ltd. (Dorset, UK). Nelfinavir and 
rapamycin were dissolved in dimethyl sulfoxide (DMSO) 
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and further diluted in culture medium to the required 
concentrations before use. Nelfinavir and salinomycin 
concentrations were chosen based on solubility and dose 
response curves carried out in Tsc2 MEFs.
Western blotting and antibodies
Cells were lysed in cell lysis buffer (20 mM Tris, 
pH 7.5, 135 mM NaCl, 5% [v/v] glycerol, 50 mM NaF, 
0.1% [v/v] Triton X-100, plus protease inhibitors), 
centrifuged and protein quantified using Bradford reagent 
(Sigma-Aldrich). Samples were made up in NuPAGE 
LDS sample buffer (Life Technologies). Western blotting 
was performed as previously described [28]. Blots shown 
are representative of 3 independent experiments. Anti-β-
actin (#4967), phospho-TSC2 S1387 (#5584), total TSC2 
(#3990), IRE1α (3294S), phospho-S6K1 T389 (#9205), 
total S6K1 (#9202), phospho-rpS6 S235/236 (#2211), 
total rpS6 (#2217), phospho-4E-BP1 S65 (#9451), total 
4E-BP1 (#9644), phospho-ACC S79 (#3661), total 
ACC (#3676), PARP (#9542), caspase 3 (#9662), ATF4 
(#11815), phospho-FOXO3a (#9466S), total FOXO3a 
(#9467), phospho-PRAS40 T246 (#2997), total PRAS40 
(#2691) and phospho-Bad S136 (#4366) antibodies were 
from Cell Signaling Technology (Danvers, MA, USA). 
GADD34 antibody (10449-1-AP) was from Proteintech 
(Manchester, UK).
RNA extraction, Q-PCR and XBP1 splicing
This was performed as described previously [16] 
with the additional use of HSP70 and EDEM1 real time 
Quantitect PCR primers which were obtained from Qiagen 
(West Sussex, United Kingdom).
Flow cytometry
To measure cell death prevalence in the population, 
drug treated cells were trypsinised from 24 well plates and 
incubated with 3 µM DRAQ7TM (Biostatus Ltd, Shepshed, 
UK) for 10 min at 37 ˚C. Flow cytometry was performed 
using a FACS Calibur flow cytometer (Becton Dickinson, 
Cowley, UK) using excitation at 488 nm and detection of 
fluorescence in log mode at wavelengths greater than 695 
nm (far red). Cell Quest Pro software (Beckton Dickinson 
Immunocytometry Systems) was used for signal 
acquisition. Autofluorescence of unstained cells provided 
the background readout across all samples. Correlated 
signals were collected for a minimum of 10,000 events. 
Events were gated and analysed using FlowJo software 
(Oregon, USA).
Synergy analysis using compuSyn
Cell viability obtained through flow cytometry 
analysis was inputted into CompuSyn software 
(ComboSyn, Inc, [29]) to obtain Combination Index 
(CI) values using a non-constant ratio approach. Flow 
cytometry values used were the mean of three independent 
experiments.
Proteasome assay
Proteasomes were extracted from live cells 2 
h post-treatment according to a previously described 
protocol [30]. Chymotrypsin-like proteasome activity 
was assessed using the fluorogenic substrate Succ-LLVY-
AMC (Sigma). Assays were performed as described 
(Crawford et al, 2006), with the rate of substrate turnover 
determined by monitoring the fluorescence of released 
aminomethylcoumarin using a multiwell plate reader 
(FLUOstar Optima, BMG Labtech) at an excitation 
wavelength of 395 nm and emission wavelength of 460 
nm over a period of 35 min.
Soft agar assays
Two-layered soft agar assays were performed in 6 
well plates using a base layer of 0.6 % agar in standard 
culture media. Tsc2-/- MEFs or AML 621-102 cells (1.5 
x 105 cells per well) were suspended in a top layer of 0.3 
% (w/v) agar. Complete media containing the indicated 
treatments was added the following day. Cultures were 
grown for 11 days, with media (and drug treatments) 
replaced every 2-3 days. Images were taken using an 
EVOS XL Core camera (Life Technologies).
3D spheroids and outgrowth
Tsc2-/- MEFs or ELT3-V3 cells were plated at 1000 
cells/well into a 96-well plate, precoated with 1.5 % 
(w/v) agarose. Spheroids were allowed to form for 72 h 
before treatment with DMSO, 10 µM nelfinavir and 2 µM 
salinomycin or 25 nM rapamycin. Fresh media and drugs, 
including DRAQ7 (which is non-toxic), were added by 
removal and replacement of 50 % of the media volume 
after 60 h, and incubated for a further 36 h (total 96 h 
treatment incubation). Dual channel images were acquired 
using a Zeiss Axio Observer Z1 microscope (Carl Zeiss 
Microimaging, Gottingen, Germany) with a black box 
chamber (Solent Scientific Ltd, Segensworth, U.K.) at 0 
and 96 h timepoints. Spheroid size (transmission mode) 
and DRAQ7 labelling (fluorescence excitation 488nm/
emission above 695nm) were assessed using MetaMorph 
acquisition software. Following imaging, spheroids were 
transferred to a standard, tissue culture coated 24 well plate 
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with fresh culture media (no drug treatments) and imaged 
using an EVOS XL Core camera (Life Technologies) after 
0, 24, 48 and 72 h. Total outgrowth area from the spheroid 
was measured using ImageJ (v1.50i) software (https://
imagej.nih.gov/ij/).
Statistical analysis
All reported flow cytometry and soft agar assay 
results are from three independent experiments. 
Proteasome assays were independently performed three 
times in duplicate. 3D spheroid data was from an average 
of 10 spheroids per condition and repeated across three 
independent experiments. All statistical analyses were 
conducted using SPSS20 (IBM). Data are graphed as the 
mean ± SEM. Multiple data sets were compared using one 
way ANOVA, followed by the LSD post-hoc test. 
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